Isoxepac

Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases[1][2][3].

Product Specifications

CAS Number

[55453-87-7]

Product Name Alternative

HP 549

UNSPSC

12352005

Hazard Statement

H301

Target

Drug Derivative

Type

Reference compound

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/isoxepac.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CC1=CC=C(C2=C1)OCC3=CC=CC=C3C2=O

Molecular Formula

C16H12O4

Molecular Weight

268.27

Precautions

H301

References & Citations

[1]L S Gerlis, et al. Isoxepac in rheumatoid arthritis: a double-blind comparison with aspirin. Rheumatol Rehabil. 1981 Feb 1;20 (1) :50-3.|[2]W J Honig, et al. Analgesic effect of isoxepac on postmeniscectomy pain: a controlled trial. J Clin Pharmacol. Feb-Mar 1982;22 (2-3) :82-8.|[3]H P Illing, et al. Species differences in the disposition and metabolism of 6,11-dihydro-11-oxodibenz[be]oxepin-2-acetic acid (isoxepac) in rat, rabbit, dog, rhesus monkey, and man. Drug Metab Dispos. Sep-Oct 1978;6 (5) :510-7.